SAKAR2022-10-012022-12-31 SAKAR2022-10-012022-12-31 SAKAR2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member SAKAR2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member SAKAR2022-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 000000 SAKAR NOTLISTED Sakar Healthcare Limited Equity 2022-04-01 2023-03-31 2023-02-10 2023-02-01 INR Lakhs Third quarter 14:00:00 14:30:00 2023-02-10 2023-02-10 Not applicable Single segment Pharmaceuticals 2022-10-01 2022-12-31 Unaudited Standalone 334653000.00 18539000.00 353192000.00 190763000.00 0.00 -10183000.00 47260000.00 19446000.00 40961000.00 18813000.00 307060000.00 46132000.00 0.00 46132000.00 7054000.00 -1049000.00 6005000.00 0.00 40127000.00 0.00 0.00 0.00 0.00 40127000.00 -583000.00 39544000.00 39544000.00 0.00 186180000.00 10 2.16 2.16 0.00 0.00 2.16 2.16 1. The Company is operating only in one segment. Hence segment reporting is not given. 2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder 3. The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate. 4. Provision for taxation/deferred taxation, if any, will be made at the year end 5. Figures, wherever required, are regrouped / rearranged 6. The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 10th February, 2023 Please note that in NSE utility under Tax Expense only two column are avilable hence we have clubed Deferred tax and MAT Credit Entitlement as under; 1. Deferred tax i.e. Rs. -10.49 lacs covered Deferred tax of Rs. 60.05 lacs and MAT Credit Entitlement of Rs. (70.54) lacs in quarterly column i.e quarter edned 31.12.2022 AND 2. Deferred tax i.e. Rs. 198.28 lacs covered Deferred tax of Rs. 415.20 lacs and MAT Credit Entitlement of Rs. (219.92) lacs in 9 month ended column i.e 9 month ended on 31.12.2022 Single segment 2022-04-01 2022-12-31 Unaudited Standalone 927080000.00 28570000.00 955650000.00 532039000.00 0.00 -21301000.00 114298000.00 37958000.00 114316000.00 48459000.00 825769000.00 129881000.00 0.00 129881000.00 0.00 41520000.00 41520000.00 0.00 88361000.00 0.00 0.00 0.00 0.00 88361000.00 -1750000.00 86611000.00 86611000.00 0.00 186180000.00 10 4.75 4.75 0.00 0.00 4.75 4.75 Other Expenses 18813000.00 Other Expenses 48459000.00 -808000.00 -2425000.00 -225000.00 -675000.00 0.00 0.00